Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.34 |
| ▸ | KLKB1 known ✓ | P03952 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.34 |
| ▸ | FEN1 | P39748 | 9/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 3/20 | 0.32 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20797816 | 0.98 | KCNH2 (0.36) | ALOX5APFEN1KCNH2KLKB1DGAT1 | |
| SCHEMBL17225037 | 0.98 | ALOX5AP (0.35) | ALOX5APFEN1KCNH2KLKB1DGAT1 | |
| Hydrochloric Acid SCHEMBL17225077 | 0.93 | ALOX5AP (0.40) | ALOX5APFEN1 | |
| SCHEMBL17236145 | 0.91 | ALOX5AP (0.41) | ALOX5APFEN1 | |
| SCHEMBL18315116 | 0.79 | KLKB1 (0.35) | KLKB1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL17225047 | 0.79 | PDE10A (0.36) | KLKB1DGAT1NOS3NOS1NOS2 | |
| SCHEMBL17236176 | 0.76 | PDE10A (0.37) | KLKB1DGAT1NOS3NOS1NOS2 | |
| SCHEMBL17225041 | 0.76 | CYP17A1 (0.36) | ALOX5APFEN1KCNH2 | |
| SCHEMBL24784940 | 0.76 | KRAS (0.34) | KLKB1NOS3NOS1NOS2 | |
| SCHEMBL20810663 | 0.75 | KCNH2 (0.49) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378223-B2 | Process for preparation of triaminopyrimidine compound and intermediates thereof | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| EP-3679030-B1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | ZYDUS LIFESCIENCES LTD (IN) | 2024-03-27 | — | — | EP | disclosed |
| EP-3679030-A1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | Cadila Healthcare Limited (IN) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207738-A1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| CN-111051299-A | Preparation method of triaminopyrimidine compound and intermediate thereof | 卡迪拉保健有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019049021-A1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2019-03-14 | — | — | WO | disclosed |
| US-9957253-B2 | Triaminopyrimidine compounds useful for preventing or treating malaria | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-05-01 | — | — | US | disclosed |
| EP-3137455-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | MMV Medicines for Malaria Venture (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170050951-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | ASTRAZENECA INDIA PRIVATE LIMITED (IN) | 2017-02-23 | — | — | US | disclosed |
| WO-2015165660-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050951-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | DPYD, TYMP, DHFR | KCNH2 3313/4885KLKB1 2993/4885ALOX5AP 1006/4885 |
| US-12378223-B2 | Process for preparation of triaminopyrimidine compound and intermediates thereof | DPYD, SAMHD1, DHPS | KCNH2 2819/4885KLKB1 2210/4885ALOX5AP 680/4885 |
| US-20200207738-A1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | DPYD, SAMHD1, NUDT1 | KCNH2 2843/4885KLKB1 2520/4885ALOX5AP 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.